Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients.
J Crit Care
; 51: 117-121, 2019 06.
Article
em En
| MEDLINE
| ID: mdl-30802757
ABSTRACT
PURPOSE:
Previously, higher circulating levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor matrix metalloproteinases (TIMP)-1 were reported in the first hours after TBI in blood samples from patients with poor prognosis. Thus, the objectives of this study were to determine whether MMP-9 and TIMP-1 levels during the first week of a severe TBI could be used as biomarker predictive of mortality.METHODS:
We included patients with severe TBI (defined as Glasgow Coma Scale lower than 9), and with Injury Severity Score in non-cranial aspects lower than 9. We determined serum concentrations of MMP-9 and TIMP-1 at days 1, 4 and 8 of TBI.RESULTS:
TIMP-1 concentrations at days 1 (pâ¯<â¯.001), 4 (pâ¯=â¯.001), and 8 (pâ¯=â¯.01) of TBI were higher in non-surviving (nâ¯=â¯34) than in surviving (nâ¯=â¯90) patients. ROC curve analyses showed an area under curve of TIMP-1 concentrations at days 1, 4, and 8 of TBI to predict 30-day mortality of 78% (pâ¯<â¯.001), 76% (pâ¯<â¯.001) and 71% (pâ¯=â¯.02) respectively.CONCLUSIONS:
The most relevant new findings of our study were that TIMP-1 levels during the first week of a severe TBI were higher in non-surviving than in surviving patients and that could be used as biomarker predictive of mortality.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Inibidor Tecidual de Metaloproteinase-1
/
Metaloproteinase 9 da Matriz
/
Lesões Encefálicas Traumáticas
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article